This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Laakso, M. Search for Related Content PubMed PubMed Citation Articles by Laakso, M. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Blood Pressure Medicines Diabetes High Blood Pressure Related Collections Cardiovascular Pharmacology Other hypertension Chronic ischemic heart disease

(Circulation. 1999;99:461-462.)
© 1999 American Heart Association, Inc.

Cardiovascular News

Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes

Lessons From the UK Prospective Diabetes Study

Markku Laakso, MD

From the Department of Medicine, University of Kuopio, Kuopio, Finland.

Correspondence to Markku Laakso, MD, Professor and Chair, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail markku.laakso@uku.fi

For decades, the treatment of type 2 diabetes has been based more on assumptions than on facts. Even the most crucial question—does a reduction in blood glucose help to prevent long-term complications—has remained unanswered. Now, 4 reports from the United Kingdom Prospective Diabetes Study (UKPDS)^{1 2 3 4} offer useful information on the benefits of treating hyperglycemia and hypertension in this disorder.

Whereas the complications of type 1 diabetes are chiefly microvascular, patients with type 2 diabetes are prone to accelerated atherosclerosis.⁵ The most important macrovascular complication is coronary heart disease (CHD), which causes almost half the deaths in these patients. Although classic risk factors (ie, high total cholesterol, hypertension, and smoking) play a substantial part in pathogenesis, they do not explain the excess of macrovascular complications in type 2 diabetes. Therefore, the specific risk factors, particularly hyperglycemia, have been given increasing attention. In population-based prospective studies, hyperglycemia has indeed proved to be associated with risk of CHD in type 2 diabetes: a 1% change in glycohemoglobin (HbA_1c) signifies about a 10% change in risk of CHD.^{6 7} Thus, there is potential, albeit modest, for reducing CHD events by lowering blood glucose.

Control of Hyperglycemia

What is the evidence that improvement in glycemic control is beneficial in this respect? The first study aiming to address this question, the University Group Diabetes Program (UGDP), published in the 1970s,⁸ randomized 200 patients with type 2 diabetes to phenformin, tolbutamide, a fixed insulin dose, a variable insulin dose, or placebo. With phenformin and tolbutamide, cardiovascular mortality was higher than . . . [Full Text of this Article]

This article has been cited by other articles:

				R. R. Henry Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management Clin. Diabetes, July 1, 2001; 19(3): 113 - 120. [Abstract] [Full Text] [PDF]

				P. C. Deedwania Hypertension and Diabetes: New Therapeutic Options Arch Intern Med, June 12, 2000; 160(11): 1585 - 1594. [Abstract] [Full Text] [PDF]